| Literature DB >> 28638827 |
Jiewen Jin1, Weimin Wang1, Liangying Zhu1, Tianwei Gu1, Qing Niu2, Ping Li1, Yan Bi1, Dalong Zhu1.
Abstract
AIM: This study aimed to evaluate the association between cardiovascular autonomic neuropathy (CAN) and left ventricular diastolic dysfunction (LVDD) in type 2 diabetes patients.Entities:
Mesh:
Year: 2017 PMID: 28638827 PMCID: PMC5468548 DOI: 10.1155/2017/3270617
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
General characteristics of study population.
| NCAN | PCAN | DCAN |
| |
|---|---|---|---|---|
|
| 36 | 161 | 118 | — |
| Age (year) | 54.2 ± 11.8 | 57.1 ± 11.2 | 60.4 ± 8.0 | 0.002 |
| Duration of diabetes (year) | 7.9 ± 6.3 | 10.2 ± 7.4 | 12.9 ± 7.6 | 0.000 |
| Male sex (%) | 72.2 | 61.3 | 57.6 | 0.290 |
| BMI (kg/m2) | 24.7 ± 3.5 | 25.2 ± 3.5 | 25.2 ± 4.0 | 0.768 |
| Waistline (cm) | 90.7 ± 7.1 | 91.6 ± 8.0 | 93.2 ± 9.9 | 0.215 |
| FBG (mmol/L) | 7.8 ± 2.1 | 8.0 ± 2.4 | 8.6 ± 2.4 | 0.065 |
| HbA1c (%) | 9.2 ± 1.7 | 8.9 ± 2.2 | 9.2 ± 2.1 | 0.440 |
| Triglycerides (mmol/L) | 2.01 ± 1.29 | 1.70 ± 1.02 | 1.82 ± 1.28 | 0.309 |
| Total cholesterol (mmol/L) | 4.29 ± 0.77 | 4.07 ± 1.18 | 4.49 ± 1.50 | 0.033 |
| HDL cholesterol (mmol/L) | 0.97 ± 0.31 | 1.05 ± 0.30 | 1.09 ± 0.33 | 0.133 |
| LDL cholesterol (mmol/L) | 2.28 ± 0.63 | 2.24 ± 0.84 | 2.52 ± 0.82 | 0.022 |
| Pulse pressure (mmHg) | 49.3 ± 9.0 | 50.6 ± 13.2 | 54.2 ± 12.4 | 0.027 |
| Resting heart rate (bpm) | 69.3 ± 8.5 | 69.1 ± 9.1 | 69.0 ± 10.6 | 0.991 |
| QTc (ms) | 407.6 ± 19.2 | 411.0 ± 16.9 | 415.5 ± 16.3 | 0.027 |
| Retinopathy (%) | 29.0 | 29.3 | 48.1 | 0.005 |
| Nephropathy (%) | 27.8 | 28.2 | 27.1 | 0.979 |
| DSPN (%) | 24.1 | 27.3 | 52.3 | 0.000 |
| Current smoker (%) | 44.4 | 26.4 | 28.8 | 0.097 |
| Family history of diabetes (%) | 22.2 | 36.8 | 52.5 | 0.002 |
| History of hypertension (%) | 38.9 | 58.3 | 55.1 | 0.957 |
Data are presented as means ± SD or n (%). BMI, body mass index; FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; QTc, corrected QT interval; DSPN, diabetic sensorimotor polyneuropathy. P < 0.05; P < 0.01.
Assessment of left ventricular diastolic function by the stage of CAN.
| NCAN | PCAN | DCAN |
| |
|---|---|---|---|---|
|
| 36 | 161 | 118 | — |
| EF (%) | 61.0 ± 2.3 | 60.2 ± 2.9 | 60.5 ± 1.9 | 0.228 |
|
| 0.74 ± 0.14 | 0.74 ± 0.18 | 0.71 ± 0.17 | 0.377 |
|
| 0.78 ± 0.20 | 0.77 ± 0.20 | 0.88 ± 0.16 | 0.000 |
|
| 1.01 ± 0.36 | 0.99 ± 0.32 | 0.83 ± 0.23 | 0.000 |
|
| 8.6 ± 2.4 | 8.3 ± 3.1 | 6.8 ± 1.7 | 0.000 |
|
| 9.4 ± 2.8 | 9.8 ± 2.8 | 10.9 ± 2.7 | 0.006 |
| LV mass (g) | 145.9 ± 28.6 | 153.0 ± 31.6 | 167.5 ± 40.3 | 0.000 |
| LVMI (g/m2) | 83.8 ± 13.3 | 87.1 ± 16.1 | 95.8 ± 19.1 | 0.000 |
| LVDD (%) | 39.4 | 45.3 | 68.0 | 0.001 |
Data are presented as means ± SD or n (%). E, early diastolic filling velocity; A, late diastolic filling velocity; e′, early diastolic mitral annulus velocity; LVMI, left ventricular mass index; LVDD, left ventricular diastolic dysfunction. P < 0.01.
Correlation between CAN assessment parameters and echocardiography indicators for diastolic dysfunction.
| HRV_DP | HRV_Valsalva | HRV 30 : 15 | BPV | |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
|
| 0.156 | 0.009 | 0.136 | 0.117 | 0.309 | 0.000 | 0.072 | 0.202 |
|
| 0.227 | 0.001 | 0.216 | 0.031 | 0.224 | 0.000 | 0.016 | 0.804 |
|
| −0.176 | 0.010 | −0.205 | 0.041 | −0.211 | 0.001 | 0.095 | 0.143 |
| LV mass | −0.203 | 0.001 | −0.118 | 0.172 | −0.131 | 0.020 | −0.081 | 0.150 |
| LVMI | −0.158 | 0.009 | −0.115 | 0.183 | −0.211 | 0.000 | −0.086 | 0.134 |
E, early diastolic filling velocity; A, late diastolic filling velocity; e′, early diastolic mitral annulus velocity; LVMI, left ventricular mass index; HRV_DP, heart rate variation during deep breathing; HRV_Valsalva, heart rate variation during Valsalva maneuver; HRV 30 : 15, heart rate variation during the lying-to-standing test; BPV, blood pressure variability in response to standing up. P < 0.05; P < 0.01.
Multivariate analysis of the correlation between selected variables and LVDD.
| Variables | OR | 95% CI |
|
|---|---|---|---|
| Age (year) | 1.052 | 1.022–1.083 | 0.001 |
| Gender (male/female) | 1.483 | 0.451–4.790 | 0.513 |
| Duration of diabetes (year) | 1.009 | 0.971–1.049 | 0.644 |
| Current smoker (yes/no) | 1.449 | 0.797–2.635 | 0.224 |
| LDL (mmol/L) | 0.905 | 0.683–1.119 | 0.498 |
| HbA1c (%) | 0.894 | 0.732–1.069 | 0.222 |
| Pulse pressure (mmHg) | 0.993 | 0.938–1.042 | 0.778 |
| QTc (ms) | 0.981 | 0.957–1.016 | 0.379 |
| CAN stage | 1.628 | 1.131–2.344 | 0.009 |
LVDD, left ventricular diastolic dysfunction; LDL, low-density lipoprotein; HbA1c, glycosylated hemoglobin; QTc, corrected QT interval; CAN, cardiovascular autonomic neuropathy. P < 0.01.